Technology | December 11, 2013

C4 Imaging Announces FDA 510(k) Clearance of Sirius Positive-Signal MRI Marker

Mri systems brachytherapy prostate technology c4 imaging sirius mri marker
December 11, 2013 — C4 Imaging LLC announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its first product, the Sirius MRI Marker. The positive-signal magnetic resonance imaging (MRI) marker will be used following treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a single post-implant MRI procedure.
 
Brachytherapy, or radioactive seed implantation, is a standard option for the curative treatment of prostate cancer. Brachytherapy involves implanting around 100 radioactive seeds into the prostate. Its popularity has increased due to its effectiveness, convenience, relatively low incidence of erectile dysfunction and minimal invasiveness [1]. Radiation released from the seeds penetrates the surrounding prostate tissue at a limited distance, with most of the radiation concentrated within the prostate. Outcomes after brachytherapy depend greatly on the quality of the implant: eight-year prostate-specific antigen (PSA) relapse-free survival rates of 93 percent for high-quality implants versus 76 percent for low-quality implants have been reported [2].
 
"A Positive-Signal MRI marker can enhance seed detection. This represents a significant advancement for prostate brachytherapy," said Steven Frank M.D., founder and chairman, C4 Imaging. "If seeds can be readily localized with MRI, it would lead to more effective treatment and better patient outcomes."
 
"The encapsulation of a contrast agent within a permanently implantable device allows positive MRI seed localization after brachytherapy to be offered to more than 200,000 men diagnosed with prostate cancer in the U.S. each year [3]," said Andrew Bright, president and CEO, C4 Imaging.
 
"With our 510(k) now cleared, we're actively pursuing options for supplying Sirius to physicians treating prostate cancer in the U.S., as well as seeking regulatory clearance in Canada and Europe,” Bright added.
 
For more information: www.c4imaging.com
 
References
[1] Frank SJ, et al. American College of Radiology Appropriateness Criteria Permanent Source Brachytherapy for Prostate Cancer. Brachytherapy. 2011; 10(5): 357-362.
[2] Zelefsky MJ, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int. J.   Radiat. Oncol. Biol. Phys. 2007; 67(2): 327-333.
[3] American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013.

Related Content

Philips Introduces Technology Maximizer Program for Imaging Equipment Upgrades
Technology | Imaging | January 17, 2018
January 17, 2018 — Philips recently announced the launch of Technology Maximizer, a cross-modality program designed t
Russian Team Developing New Technology to Significantly Reduce MRI Research Costs
News | Magnetic Resonance Imaging (MRI) | January 16, 2018
January 16, 2018 — Researchers from the NUST MISIS Engineering Center for Industrial Technologies in Russia have deve
Smartphone Addiction Creates Imbalance in Brain
News | Mobile Devices | January 11, 2018
Researchers have found an imbalance in the brain chemistry of young people addicted to smartphones and the internet,...
Emergency Radiologists See Inner Toll of Opioid Use Disorders

Rates of Imaging Positivity for IV-SUDs Complications. Image courtesy of Efren J. Flores, M.D.

News | Clinical Study | January 11, 2018
January 11, 2018 – Emergency radiologists are seeing a high prevalence of patients with complications related to opio
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Weight Loss Through Exercise Alone Does Not Protect Knees
News | Orthopedic Imaging | January 11, 2018
January 11, 2018 – Obese people who lose a substantial amount of weight can significantly slow down the degeneration
Neurofeedback Shows Promise in Treating Tinnitus

The standard approach to fMRI neurofeedback. Image courtesy of Matthew Sherwood, Ph.D.

News | Magnetic Resonance Imaging (MRI) | January 11, 2018
January 11, 2018 — Researchers using...
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
State-of-the-Art MRI Technology Bypasses Need for Biopsy
News | Magnetic Resonance Imaging (MRI) | January 09, 2018
January 9, 2018 – The most common type of tumor found in the kidney is generally quite small (less than 1.5 in).
New Studies Show Brain Impact of Youth Football
News | Neuro Imaging | January 09, 2018
School-age football players with a history of concussion and high impact exposure undergo brain changes after one...
Overlay Init